

REFERENCES

1. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. *Ann Oncol* 2013;24:152-60.
2. Tang LH, Basturk O, Sue JJ, Klimstra DS. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. *Am J Surg Pathol* 2016;40:1192-202.
3. Reubi JC. Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. *Neuroendocrinology*. 2004;80 (Suppl 1):51–56.
4. Lloyd R.V, Osamura R.Y, Kloppel G, Rosai J (Eds): WHO classification of tumors of endocrine organs (4th edition). IARC: Lyon 2017
5. National comprehensive cancer network. Neuroendocrine and adrenal tumors (Version 3 2018)
6. Veilayoudom-Ce'phise FL, Duvillard P, Foucan L et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? *Endocr Relat Cancer* 2013;20: 649–657.